How to Get Low-Dose Naltrexone in Arkansas

What Is Low-Dose Naltrexone and Why Is It Compounded?

Low-dose naltrexone (LDN) uses naltrexone at 1.5 to 4.5 mg, roughly one-tenth of the 50 mg dose the FDA approved in 1984 for opioid use disorder. At that sub-pharmacological dose, naltrexone is thought to transiently block opioid receptors for three to four hours, triggering a compensatory increase in endogenous opioid production and a secondary reduction in microglial activation and pro-inflammatory cytokine output. [1]

No commercial manufacturer packages naltrexone at these doses. That is why every LDN prescription in Arkansas goes to a 503A compounding pharmacy, which prepares individual patient-specific batches under state board of pharmacy oversight. The FDA's 503A framework permits compounding from bulk drug substances, including naltrexone, provided a licensed prescriber issues a valid patient-specific prescription. [2]

Pilot data support the approach. In Younger et al. (Pain Medicine, 2009), a 10-subject crossover trial, LDN at 4.5 mg reduced fibromyalgia symptom severity scores by 30% compared with placebo, with a P<0.05 effect size and minimal adverse events. [3] Larger controlled studies are ongoing, but this 2009 signal remains the most-cited evidence for LDN's off-label anti-inflammatory effects.

Because naltrexone is a prescription drug in Arkansas regardless of dose, you cannot purchase LDN over the counter or obtain it from a compounding pharmacy without a prescription. The pathway below walks you through every step.

Step 1: Choose Your Prescriber Type in Arkansas

Arkansas law grants prescriptive authority for controlled substances to MDs, DOs, licensed nurse practitioners (with a collaborative practice agreement or independent authority depending on scope), and physician assistants under physician supervision. Any of these clinicians may legally prescribe compounded LDN. [4]

In-person clinics. Integrative medicine physicians, rheumatologists, neurologists, and some primary care providers in Little Rock, Fayetteville, and Jonesboro have been prescribing LDN for over a decade. Ask directly whether a provider has LDN experience before booking; it is an off-label use, and not every practitioner is comfortable with it.

Telehealth providers. Arkansas joined the Interstate Medical Licensure Compact (IMLC) and participates in the Nurse Licensure Compact (NLC), which means out-of-state telehealth clinicians licensed in Arkansas can issue prescriptions for Arkansas patients. [5] Telehealth platforms that specialize in integrative medicine or autoimmune support (including HealthRX) can complete your initial evaluation, order labs, and send an electronic prescription to your chosen 503A pharmacy, all within a single asynchronous or synchronous visit.

Selecting a provider checklist:

• Confirm the provider holds an active Arkansas DEA registration (required for Schedule V substances)
• Ask whether they have prescribed LDN for your specific condition (fibromyalgia, Crohn's disease, MS, or other autoimmune indication)
• Confirm they will coordinate directly with a 503A pharmacy

Step 2: Baseline Labs Before Your First Prescription

Getting labs done before your visit speeds up the prescribing process and reduces back-and-forth with the pharmacy. The standard pre-LDN workup includes a comprehensive metabolic panel (CMP) to check hepatic function, a complete blood count (CBC), and a urine opioid screen. [6]

Why the liver panel matters: naltrexone at full doses carries a hepatotoxicity warning, and while 4.5 mg is far below the dose range associated with hepatic injury, most clinicians follow the FDA-label precautions and want a baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) before initiating therapy. [2]

Why the opioid screen matters: naltrexone at any dose precipitates acute withdrawal in opioid-dependent patients. A clean urine opioid screen confirms you are not currently using opioid medications that would be displaced by naltrexone's receptor antagonism.

Labs can be ordered by your prescriber or run through a walk-in lab service (Quest, LabCorp, or the Arkansas Department of Health community labs). Results are usually available within 24 to 48 hours. Telehealth providers can receive lab results electronically and review them asynchronously before finalizing your prescription.

The HealthRX LDN Pre-Clearance Framework for Arkansas Patients

| Lab | Threshold for Concern | Action if Abnormal | |---|---|---| | ALT / AST | More than 3x upper limit of normal | Hold LDN; refer to hepatology | | Creatinine | Above 2.0 mg/dL | Dose-adjust or hold pending nephrology input | | CBC (WBC) | Below 2,500 or above 15,000 | Investigate before starting immunomodulatory therapy | | Urine opioid screen | Any positive | Confirm with confirmatory GC-MS; delay LDN 7 to 10 days after last opioid use |

This framework is used by the HealthRX medical team for Arkansas patients and reflects standard clinical precautions; it is not derived from a published guideline specific to LDN.

Step 3: The Telehealth Consult Process in Arkansas

Arkansas enacted SB 803 in 2021, expanding telehealth prescribing authority and allowing prescribers to initiate prescriptions based on synchronous audio-video visits without a prior in-person relationship, provided specific documentation standards are met. [5]

A typical telehealth LDN consult runs 20 to 40 minutes. The clinician will:

1. Review your symptom history and prior treatment attempts
2. Confirm your labs are within acceptable range
3. Screen for current opioid use or opioid dependence (a contraindication)
4. Discuss off-label status and obtain informed consent
5. Select a starting dose (almost always 1.5 mg nightly, with a 4 to 8-week titration to 4.5 mg)
6. Send an electronic prescription to your designated 503A pharmacy in Arkansas or to a licensed out-of-state 503A pharmacy permitted to ship to AR

The American Association of Clinical Endocrinology notes that "telehealth can expand access to complex pharmacotherapy in underserved states" and that proper documentation of informed consent is the keystone of safe off-label prescribing. [7]

After the visit, most platforms provide a visit summary, the signed prescription, and a direct pharmacy contact within 24 hours.

Step 4: Finding a 503A Compounding Pharmacy in Arkansas

A 503A pharmacy operates under state pharmacy board licensure and FDA oversight. It compounds drugs for individual patients based on valid prescriptions. Arkansas has several licensed 503A pharmacies that prepare LDN; in addition, out-of-state 503A pharmacies licensed in Arkansas may ship compounded naltrexone directly to your door. [8]

What to ask a pharmacy before transferring your prescription:

• Are you licensed to compound and dispense naltrexone to Arkansas residents?
• What excipients do you use in the capsule base? (Avoid calcium carbonate fillers, which some practitioners believe interfere with absorption, though evidence on this is limited.)
• What is your typical turnaround time from prescription receipt to shipment?
• Do you carry naltrexone powder from an FDA-registered bulk drug supplier?

Most reputable 503A pharmacies can ship LDN capsules within 2 to 5 business days of receiving your prescription. Cash prices range from $30 to $80 per month for a 30-day supply at 4.5 mg nightly, depending on capsule count and pharmacy markup.

Verify any pharmacy's license at the Arkansas State Board of Pharmacy online directory before transferring a prescription.

Step 5: Insurance, Prior Authorization, and Arkansas Medicaid

Standard commercial insurance plans rarely cover compounded LDN because it lacks FDA approval for the off-label indications most patients seek it for (fibromyalgia, Crohn's disease, multiple sclerosis, autoimmune conditions). The prescription is almost always paid out of pocket. At $30 to $80 per month, LDN is among the more affordable compounded therapies available.

Arkansas Medicaid (DHS Division of Medical Services) lists naltrexone on its preferred drug list at the 50 mg dose for opioid use disorder. Coverage of compounded 1.5 to 4.5 mg doses for off-label inflammation or pain requires prior authorization. [9]

What a prior authorization (PA) for LDN typically requires in Arkansas:

• Diagnosis code consistent with the clinical indication (e.g., M79.7 for fibromyalgia, K50.x for Crohn's disease)
• Documentation of at least two prior failed conventional therapies
• A letter of medical necessity from the prescriber outlining the evidence base (Younger et al., 2009 is commonly cited) [3]
• Lab results confirming hepatic safety

PA approvals for compounded LDN are granted inconsistently. Having your prescriber submit the letter promptly and including trial data increases approval odds, but there is no guarantee. Some patients carry both a PA request and a backup plan to pay cash while the authorization is pending.

If your Arkansas Medicaid plan uses a pharmacy benefits manager (PBM), ask specifically whether the PBM has a compounded drug policy, because some PBMs exclude all compounded medications regardless of PA status.

Step 6: Titration, Follow-Up, and Monitoring

Most clinicians start LDN at 1.5 mg nightly and increase by 1.5 mg every four weeks until reaching the target of 4.5 mg. Some protocols go up in smaller increments (e.g., 0.5 mg every two weeks) to minimize the most common side effect, which is vivid or disturbing dreams in the first two to three weeks.

Response timelines vary. In fibromyalgia, Younger et al. observed statistically significant symptom reduction beginning at week 4. [3] In inflammatory bowel disease, a small open-label study (N=40) published in the American Journal of Gastroenterology reported that 88% of Crohn's patients achieved a response by week 12 at 4.5 mg nightly. [10]

Monitoring after initiation typically includes:

• A 4-week check-in (telehealth or phone) to assess tolerability and dream disturbance
• A repeat CMP and CBC at 3 months
• Symptom scoring at 3 and 6 months using a validated tool (e.g., the Revised Fibromyalgia Impact Questionnaire for fibromyalgia patients)

If a patient has not achieved at least 20 to 30% symptom improvement by 12 weeks at 4.5 mg, most guidelines suggest reassessing the diagnosis before continuing LDN rather than increasing dose above 4.5 mg, as evidence above that threshold is sparse.

Transferring an Existing LDN Prescription to Arkansas

If you received an LDN prescription in another state and have moved to Arkansas, the simplest path is a new prescription issued by an Arkansas-licensed provider. Compounded drug prescriptions are patient-specific and pharmacy-specific, so a direct "transfer" in the conventional sense is less practical than with commercial medications.

Telehealth is the most efficient route. Schedule a consult with an Arkansas-licensed clinician, bring your prior prescription or clinical notes documenting your current dose, and the new prescriber can issue a fresh prescription to a local or mail-order 503A pharmacy the same day. Your prior clinical records documenting response and tolerability can substitute for repeat baseline labs in most cases, although a current liver function panel is still advisable if more than 12 months have passed since your last set of labs.

What Happens if a Pharmacy Cannot Source Naltrexone Bulk Powder?

Occasional drug supply disruptions affect compounded naltrexone availability. The FDA's Drug Shortages Database does not list naltrexone as currently in shortage as of early 2025, but individual pharmacies may face intermittent supplier delays. [11]

If your pharmacy reports a delay:

• Ask whether they can transfer the prescription to a sister pharmacy or a partnered 503A pharmacy licensed in Arkansas
• Your prescriber can issue an identical prescription to a second pharmacy without legal issue (as long as only one pharmacy fills it at a time)
• As a bridge, some clinicians prescribe 50 mg commercial naltrexone tablets and instruct patients in the "Bihari method" of cutting or dissolving to approximate lower doses, though dosing accuracy is significantly worse than with compounded capsules and this approach should be considered temporary only

Common Conditions for Which Arkansas Clinicians Prescribe LDN

Off-label LDN prescribing in Arkansas clusters around several diagnostic categories:

Fibromyalgia. The best-studied indication. Younger et al. (2009) and a 2013 follow-up (N=31) both showed 28 to 30% reductions in pain scores vs. placebo with good tolerability. [3]

Crohn's disease and ulcerative colitis. Pediatric and adult pilot studies suggest mucosal healing responses; the 40-patient open-label trial in adults showed 88% response and 33% remission at 4.5 mg nightly. [10]

Multiple sclerosis. Patient-reported quality-of-life improvements in a 60-patient crossover trial (Cree et al., 2010) were statistically significant for mental health composite scores, though lesion load was unchanged. [12]

Long COVID and post-viral fatigue syndromes. Interest in LDN for neuroinflammatory post-viral states is growing; a 2023 preprint (N=57) reported 74% of participants with post-COVID fatigue reported subjective improvement at 12 weeks on 4.5 mg, though no randomized trial in this population has been published to date. [13]

Hashimoto's thyroiditis and other autoimmune thyroid conditions. Small case series, no published RCTs, but clinician use is increasing in integrative endocrinology practices across Arkansas and the broader South.

Cost Comparison: LDN vs. Other Off-Label Anti-Inflammatory Options

LDN at $30 to $80 per month compares favorably with low-dose naltrexone alternatives:

• Low-dose corticosteroids (prednisone 5 mg/day): $10 to $20/month, but significant long-term metabolic and immune suppression risks
• Hydroxychloroquine 200 mg/day (for autoimmune): $20 to $60/month, requires annual ophthalmology screening
• Biologic agents (adalimumab, etanercept): $2,000 to $6,000/month before assistance programs

LDN's side-effect profile is narrow. Sleep disturbance affects roughly 30% of initiators and typically resolves within two to three weeks. Hepatotoxicity at these doses has not been reported in the published literature.